Engineered t cells take on lung cancer in early trial

NCT ID NCT02592577

Completed Disease control Sponsor: Adaptimmune Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new treatment for people with advanced non-small cell lung cancer that had grown after standard therapy. Researchers took patients' own immune cells, genetically modified them to recognize and attack cancer cells, and infused them back after chemotherapy. The main goal was to check safety and find the right dose, with 28 participants enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically modified T cells (MAGE A10ᶜ⁷⁹⁶T)
What this could lead to: If it works, this could point toward a new treatment option for advanced lung cancer that has not responded to other therapies.
What could go wrong: This is an early phase 1 trial with only 28 participants, so it is too small to prove effectiveness. The treatment involves strong chemotherapy and may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Duke University Medical Center, Duke Cancer Institute

Durham, North Carolina, 27710, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
H. Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States
Hospital Universitario 12 Octubre Avda. de Córdoba s/n

Madrid, Madrid, 28041, Spain
Hospital Universitario Fundación Jiménez Díaz

Madrid, Madrid, 28040, Spain
Indiana University Simon Cancer Center

Indianapolis, Indiana, 46033, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
Princess Margaret Cancer Centre

Toronto, Ontario, M5G1X6, Canada
Stanford Cancer Center

Palo Alto, California, 94304, United States
Tennessee Oncology- Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University College Hospital Macmillan Cancer Centre

London, WC1E 6AG, United Kingdom
University of Maryland, Greenebaum Cancer Center

Baltimore, Maryland, 21157, United States
University of Miami Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
Washington University, School of Medicine

St Louis, Missouri, 63110, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.